Loading patent…
AssigneeQueen Mary University of London
InventorsJesmond Dalli, Romain Alexandre Colas, Patricia Regina Souza
Estimating the term…
A method of treating or preventing cardiovascular disease which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin and/or upregulating or increasing the biosynthesis or activity of at least one n-3 DPA-derived resolvin. n-3 DPA-derived resolvins are normally regulated diurnally in the body and are linked to activation of platelets and leucocytes and formation of platelet-leukocyte aggregates. Dysfunctional regulation of n-3 DPA-derived resolvins may lead to systemic inflammation because of excessive inflammation-inducing eicosanoids, especially in the early hours of the morning. Further, decreased 5-LOX/15-LOX expression and increased systemic adenosine concentrations are found to be associated with reduced resolvin levels and increased risk of cardiovascular disease. n-3 DPA-derived resolvins are administered to achieve maximum absorption in the early hours. Also disclosed are n-3 DPA-derived resolvins for use in the treatment or prevention of cardiovascular disease, and methods for measuring the levels of n-3 DPA-derived resolvins and/or the expression or activity of adenosine or 5-LOX/15-LOX in biological samples obtained from a subject for assessing the subject's risk of cardiovascular disease.
A method of treating or reducing the risk of developing cardiovascular disease, vascular inflammation, or myocardial infarction, or treating dysfunctional diurnal regulation of one or more n-3 DPA-derived resolvins, or attenuating activation of platelets, or reducing formation of platelet-leukocytes aggregates in a human subject in need thereof, which comprises administering a therapeutically effective amount of at least one n-3 DPA-derived resolvin to a subject in need thereof such that tmax occurs between 7 am and 9 am and/or increasing the biosynthesis, activity or expression levels of at least one n-3 DPA-derived resolvin in a subject in need thereof such that tmax occurs between 7 am and 9 am, wherein the at least one n-3 DPA-derived resolvin is formulated for immediate or delayed and/or controlled release wherein the at least one n-3 DPA-derived resolvin is RVD1n-3 DPA, RVD2n-3 DPA and/or RvD5n-3 DPA.
Dependencies are inferred from the claim text.